TIANYU PHARM: Net profit in the third quarter was 71.4211 million yuan, a year-on-year increase of 123.90%

TIANYU PHARM announced that the revenue for the third quarter was 720 million yuan, a year-on-year increase of 7.91%; the net profit was 71.4211 million yuan, a year-on-year increase of 123.90%. The revenue for the first three quarters was 2.287 billion yuan, a year-on-year increase of 18.36%; the net profit was 221 million yuan, a year-on-year increase of 159.57%

TIANYU PHARM: Candesartan Cilexetil Tablets have completed drug registration

According to the Zhitong Finance APP, TIANYU PHARM announced that its wholly-owned subsidiary Zhejiang Nuode Pharmaceutical Co., Ltd. (referred to as "Nuode Pharmaceutical") recently received the "Drug Registration Certificate" for Candesartan Cilexetil Tablets issued by the National Medical Products Administration. Candesartan Cilexetil Tablets are indicated for primary hypertension

TIANYU PHARM released its performance for the first half of the year, with a net profit attributable to the parent company of 150 million yuan, an increase of 180.96%

According to the Zhitong Finance APP, TIANYU PHARM released its semi-annual report for 2025, showing an operating income of 1.567 billion yuan, a year-on-year increase of 23.87%. The net profit attributable to shareholders of the listed company was 150 million yuan, a year-on-year increase of 180.96%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 141 million yuan, a year-on-year increase of 125.11%. The basic earnings per share were 0.43 yuan

The A-share chemical pharmaceutical sector continues to rise, with TIBET AIM PHARM hitting the limit up, and TIANYU PHARM, CSBIO, Zhendong Pharmaceutical, Menovo, JENKEM, and GuangShengTang following suit

TIANYU PHARM signed a cooperation agreement with Heilongjiang Fengyou Biotechnology Development Co., Ltd

According to reports, recently, TIANYU PHARM signed a cooperation agreement with Heilongjiang Fengyou Biotechnology Development Co., Ltd., and the company obtained exclusive authorization for a series of patents that can be used for the development of psychotropic drugs. The company will utilize these exclusively authorized patents to develop related psychotropic drug products and enter the psychotropic drug field